Skip to main content
Premium Trial:

Request an Annual Quote

Compugen Revenues Slide

NEW YORK, Feb. 5 – Compgen today reported revenue decreases for the fourth quarter and for the year today.

The Tel Aviv, Israel-based company saw revenues fall to $11.1 million in 2002 from $11.4 million for 2001, and $2.7 million in the fourth quarter compared to $3.1 million for the year-ago quarter.

The company said it began 2003 with $67.3 million in cash and cash-related accounts with an anticipated burn rate for 2003 of $15.3 million.

Compugen said that it expects research and development expense will continue to account for over 50 percent of its total operating expenses. The company had R&D expenses of $3.6 million in the fourth quarter, compared to $3.5 million for the same quarter in 2001; and $13.6 million for the year; compared to $14.3 million in 2001.

Net loss for the year was $12.2 million, including a non-cash charge of $861,000 for amortization of deferred compensation, or $.12 a share. Net loss for the quarter ending Dec. 31, 2002, was $3.2 million, or $.12 a share, compared to $4.1 million, or $.16 a share, in the year-ago quarter.



The Scan

Missed Early Cases

A retrospective analysis of blood samples suggests early SARS-CoV-2 infections may have been missed in the US, the New York Times reports.

Limited Journal Editor Diversity

A survey finds low diversity among scientific and medical journal editors, according to The Scientist.

How Much of a Threat?

Science writes that need for a provision aimed at shoring up genomic data security within a new US bill is being questioned.

PNAS Papers on Historic Helicobacter Spread, Brain Development, C. difficile RNAs

In PNAS this week: Helicobacter genetic diversity gives insight into human migrations, gene expression patterns of brain development, and more.